AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 27 - (NewsRx.com & NewsRx.net) -- DynPort Vaccine Company LLC (DVC), which focuses on biodefense vaccines, announced that it will enter into a phase I clinical trial consisting of approximately 70 volunteers for a new, injectable recombinant anthrax vaccine.
The vaccine consists of a highly purified protein, protective antigen. Using recombinant technology and advanced production processes acquired from Avant Immunotherapeutics, Inc. (AVAN), DVC hopes this vaccine will offer a safe, effective product to support the country's need for a new-generation anthrax vaccine.
The phase I trial will be conducted at the Walter Reed Army ...
Source: HighBeam Research, Phase I vaccine clinical trial begins.(Brief Article)